Skip to content

Frontlight ResearchEarly access

Trial site

Queen Mary Hospital

Hong Kong, 999077, Hong KongNot linked to an institution yet

109running trials
62closed trials

The trials here

What the 171 trials at this site are about, from their registry records.

Conditions: Lung cancer37 trials
Hepatitis B12 trials
Liver and biliary tract cancer10 trials
Metastatic breast cancer8 trials
Gastric and oesophageal cancer6 trials
Head and neck cancer6 trials
Prostate cancer6 trials
Atrial fibrillation5 trials
Chronic kidney disease5 trials
Myeloproliferative neoplasms5 trials
Acute myeloid leukaemia4 trials
Bladder cancer4 trials
and 46 more
Phase: Phase 363 trials
Phase 222 trials
Phase 115 trials
Phase 1/210 trials
Phase 2/35 trials
Phase 44 trials
Early phase 12 trials
Status: Completed52 trials
Recruiting50 trials
Active, not recruiting46 trials
Not yet recruiting12 trials
Terminated9 trials
Enrolling by invitation1 trial
Withdrawn1 trial
Lead sponsor: The University of Hong Kong33 trials
Hoffmann-La Roche20 trials
Boehringer Ingelheim12 trials
Gilead Sciences10 trials
Bayer6 trials
and 63 more

Running trials

Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source
Not yet recruiting
E-Health Lifestyle Intervention for Arthritis: A Pilot RCT on Feasibility
NCT07786038· The University of Hong Kong· Source
Contact: Chun Man Lawrence Prof. Lau, MBChB, MRCSEd, FRCSEd(Orth), F
Recruiting
¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer
NCT07788625· The University of Hong Kong· Source
Contact: Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
Recruiting
Comprehensive Clinical Prediction Rule for Acute Heart Failure
NCT07754084· Chinese University of Hong Kong· Source
Contact: Rex PK Lam, Dr.
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07617194· Phase 1· AusperBio Therapeutics Inc.· Source
Contact: Debbie Liao
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287· Phase 2· Pfizer· Source
Recruiting
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
NCT07482943· Phase 4· The University of Hong Kong· Source
Contact: Ka Chun Timothy Dr Un
Enrolling by invitation
Can Smartphones Listen to Your Heart? A Performance Study on Detecting Inborn Heart Diseases in Your Heart Sounds
NCT07376785· The University of Hong Kong· Source
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence
NCT07839767· The University of Hong Kong· Source
Contact: Albert Chan
Not yet recruiting
Folate Treatment to Reduce Death Risk in the Year After Infection-Related Acute Kidney Injury
NCT07377071· Early phase 1· The University of Hong Kong· Source
Contact: Carrie Ip, Research nurse
Recruiting
Acupressure for Cough in Lung Cancer Survivors
NCT07315672· The University of Hong Kong· Source
Contact: Mengyao Cao
Recruiting
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
NCT07389044· Phase 1· IntegerBio· Source
Contact: Man-Fung Yuen
Recruiting
Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
NCT07444320· Boston Scientific Corporation· Source
Contact: Alice Chan
Recruiting
An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy
NCT06636188· The University of Hong Kong· Source
Contact: Tongyao Wang, PhD
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
Registry for Prostate Cancer Focal Therapy
NCT07792590· The University of Hong Kong· Source
Contact: Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
NCT07107490· Phase 1· Chugai Pharmaceutical· Source
Not yet recruiting
Atrial Fibrillation: In Search for the Optimal Target for Rate Control
NCT07135258· Phase 4· The University of Hong Kong· Source
Contact: Yap-Hang Chan
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375· Hoffmann-La Roche· Source
Active, not recruiting
Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
NCT06807970· Early phase 1· The University of Hong Kong· Source
Recruiting
Combined Injury-site & Lumbosacral Epidural Spinal Cord Stimulation
NCT07139496· The University of Hong Kong· Source
Contact: Timmy Chi Wing Chan
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Contact: Relay Therapeutics, Inc
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318· Phase 3· Takeda· Source
Contact: Yok Lam Kwong (principal investigator)
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033· Phase 3· PharmaEssentia· Source
Recruiting
Exercise Intervention as Treatment for People Using Cannabis (ExIT-C)
NCT07091292· The University of Hong Kong· Source
Contact: Albert KK Chung, MBBS(HK)
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Active, not recruiting
ASCEND CSP IDE Study
NCT06830746· Abbott Medical Devices· Source
Recruiting
Smartphone-based Self-Management Support Program to Enhance Quality of Life in Patients With COPD
NCT06888557· Hong Kong Metropolitan University· Source
Contact: Agnes YK Lai, PhD
Active, not recruiting
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
NCT06686485· Boston Scientific Corporation· Source
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235· Phase 3· Takeda· Source
Contact: Yok Lam Kwong (principal investigator)
Recruiting
Prevail Global Study
NCT06535854· Medtronic Vascular· Source
Contact: Frankie Tam (principal investigator)
Recruiting
A Communication-Priming Intervention to Improve Shared Decision-Making Between Older Adults With Advanced CKD and Clinicians
NCT06799936· The University of Hong Kong· Source
Contact: Jacqueline KY Yuen
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076· Phase 1/2· BlossomHill Therapeutics· Source
Recruiting
An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects
NCT06823635· Fondation Hôpital Saint-Joseph· Source
Contact: Raymond N. Haddad, MD, MHSc, PhDc
Active, not recruiting
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985· Phase 2· Coherus Oncology, Inc.· Source
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193· Phase 1· Olema Pharmaceuticals, Inc.· Source
Contact: There may be multiple sites in this clinical trial Olema Clinical Trial Lead
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Acupressure on Xerostomia in Head and Neck Cancer Patients
NCT06465628· The University of Hong Kong· Source
Contact: Denise Cheung, Dr.

Showing 50 of 109.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer14 recruiting
Prostate cancer4 recruiting
Bronchiectasis3 recruiting
Chronic kidney disease3 recruiting
Colorectal cancer3 recruiting
Congenital heart disease3 recruiting
Coronary artery disease3 recruiting
Hepatitis B3 recruiting
Atrial fibrillation2 recruiting
Haemophilia2 recruiting
Head and neck cancer2 recruiting
Heart failure2 recruiting
High blood pressure2 recruiting
Immune thrombocytopenia (ITP)2 recruiting
Liver and biliary tract cancer2 recruiting
Lupus (SLE)2 recruiting
Metastatic breast cancer2 recruiting
Mild cognitive impairment2 recruiting
Obstructive sleep apnoea2 recruiting
Acute myeloid leukaemia1 recruiting
Brain metastases1 recruiting
Childhood cancers1 recruiting
COPD1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Endometriosis1 recruiting
Neuroendocrine tumours1 recruiting
Obesity1 recruiting
Osteoarthritis1 recruiting
Peripheral artery disease1 recruiting
Sarcoma1 recruiting
Schizophrenia1 recruiting
Spinal cord injury1 recruiting
Thyroid cancer1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Completed
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
NCT06352892· Phase 1· Amgen· Source
Completed
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
NCT06257017· Phase 2· Yung NA· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
Instant Message-guided Hypertension Management Intervention Among Stroke Survivors
NCT06195969· The University of Hong Kong· Source
Terminated
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
NCT05763576· Phase 1· Hoffmann-La Roche· Source
Completed
A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
NCT05717686· Phase 1· AusperBio Therapeutics Inc.· Source
Completed
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
NCT05653271· Phase 1· Acepodia Biotech, Inc.· Source
Completed
Efficacy of VTP-300 in Chronic Hepatitis B Infection
NCT05343481· Phase 2· Barinthus Biotherapeutics· Source
Completed
Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD)
NCT05292547· The University of Hong Kong· Source
Terminated
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
NCT05497453· Phase 1/2· Omega Therapeutics· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Gilead Sciences· Source
Completed
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
NCT05411133· Phase 1· Arbele Pty Ltd· Source
Completed
Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
NCT05169268· The University of Hong Kong· Source
Completed
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
NCT05223920· Phase 2· Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)· Source
Terminated
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT04958785· Phase 2· Gilead Sciences· Source
Completed
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
NCT04980482· Phase 2· Arbutus Biopharma Corporation· Source
Terminated
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
NCT05166577· Phase 1· Viracta Therapeutics, Inc.· Source
Completed
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
NCT05047263· Phase 3· Bayer· Source
Terminated
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
NCT04854499· Phase 2· Gilead Sciences· Source
Completed
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
NCT04891770· Phase 2· Gilead Sciences· Source
Terminated
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
NCT04778397· Phase 3· Gilead Sciences· Source
Completed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344· Phase 3· Hoffmann-La Roche· Source
Completed
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT04771273· Phase 2· Boehringer Ingelheim· Source
Completed
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
NCT04681131· Phase 2· BioAtla, Inc.· Source
Completed
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797· Phase 2/3· Hoffmann-La Roche· Source
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source
Terminated
Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion
NCT04669223· The University of Hong Kong· Source
Completed
Roflumilast in Non-CF Bronchiectasis Study (2019)
NCT04322929· Phase 2· The University of Hong Kong· Source
Completed
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
NCT04540211· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
NCT04536337· Phase 1· Aligos Therapeutics· Source
Completed
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
NCT04435626· Phase 3· Bayer· Source
Completed
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
NCT04526106· Phase 1/2· Elevar Therapeutics· Source
Withdrawn
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
NCT05867056· Phase 1· Immunocore Ltd· Source
Completed
A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
NCT04225715· Phase 2· Hoffmann-La Roche· Source
Completed
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
NCT04321031· Phase 2· Pfizer· Source
Completed
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
NCT03938792· Phase 3· Pfizer· Source
Completed
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
NCT04000737· Phase 2· Yiviva Inc.· Source
Completed
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT04102098· Phase 3· Hoffmann-La Roche· Source
Completed
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
NCT04281576· NovoCure Ltd.· Source
Completed
Pre-Surgery If Needed for Oesophageal Cancer
NCT03937362· Shanghai Chest Hospital· Source
Completed
Substance Misuse To Psychosis for Stimulants
NCT03485417· Phase 2/3· The University of Hong Kong· Source
Completed
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT03596866· Phase 3· Takeda· Source
Completed
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
NCT03535740· Phase 2· Ariad Pharmaceuticals· Source
Completed
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
NCT03468426· Phase 1· Boehringer Ingelheim· Source
Completed
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488· Phase 1/2· BioAtla, Inc.· Source
Completed
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NCT03377491· Phase 3· NovoCure Ltd.· Source
Completed
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
NCT03315455· Phase 3· Hoffmann-La Roche· Source
Completed
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
NCT03425279· Phase 1/2· BioAtla, Inc.· Source
Completed
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
NCT03194893· Phase 3· Hoffmann-La Roche· Source
Terminated
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
NCT03194646· Phase 3· Bayer· Source

Showing 50 of 62.

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error